SCHEMBL5046183

SCHEMBL5046183

COC(=O)c1ccc(C(=O)NC(C)c2ccc(-c3ccccc3OC)s2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.48
APP P05067 1/20 0.46
CHRNA7 P36544 1/20 0.45
HDAC3 O15379 3/20 0.43
HDAC4 P56524 3/20 0.43
HDAC1 Q13547 3/20 0.43
HSD17B1 P14061 2/20 0.43
HSD17B2 P37059 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KRAS P01116 2/20 0.42
SOS1 Q07889 2/20 0.42
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CNR1 P21554 1/20 0.40
CHEK1 O14757 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5643716 0.82 HDAC6 (0.68) HDAC6APPCHRNA7HSD17B1HSD17B2
SCHEMBL5046589 0.76 ALDH1A1 (0.53) HDAC6HDAC3HDAC4HDAC1NPSR1
SCHEMBL5566270 0.75 HDAC6 (0.47) HDAC6APPCHRNA7HDAC3HDAC4
SCHEMBL6030805 0.74 HDAC3 (0.76) HDAC6HDAC3HDAC4HDAC1HSD17B10
SCHEMBL6030810 0.74 HDAC3 (0.76) HDAC6HDAC3HDAC4HDAC1HSD17B10
SCHEMBL6030315 0.73 ALDH1A1 (0.51) HDAC6HDAC3HDAC4HDAC1ALDH1A1
SCHEMBL5924607 0.72 HPGD (0.71) HDAC6APPCHRNA7HSD17B1HSD17B2
SCHEMBL1588287 0.72 NPSR1 (0.51) HDAC6HDAC3HDAC4HDAC1NPSR1
SCHEMBL27565412 0.71 HDAC6 (0.68) HDAC6APPCHRNA7HSD17B1HSD17B2
SCHEMBL5566265 0.70 HSD17B2 (0.53) HDAC6APPCHRNA7HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7396944-B2 Thiophene derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2008-07-08 US disclosed
US-20070232602-A1 Thiophene Derivatives, Their Manufacture and Use as Pharmaceutical Agents HOFFMAN-LA ROCHE INC. 2007-10-04 US disclosed
EP-1778683-A1 THIOPHENE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-05-02 EP disclosed
WO-2005121134-A1 THIOPHENE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232602-A1 Thiophene Derivatives, Their Manufacture and Use as Pharmaceutical Agents TPMT, ABCB1, CYP3A5 HDAC6 2324/4885APP 1764/4885CHRNA7 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.